KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Capital Leases (2021 - 2025)

Bionano Genomics (BNGO) has disclosed Capital Leases for 5 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Capital Leases fell 1.67% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 1.67% year-over-year, with the annual reading at $3.5 million for FY2025, 1.67% down from the prior year.
  • Capital Leases hit $3.5 million in Q4 2025 for Bionano Genomics, roughly flat from $3.5 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.6 million in Q4 2021 to a low of $3.5 million in Q4 2025.
  • Historically, Capital Leases has averaged $3.6 million across 5 years, with a median of $3.6 million in 2023.
  • Biggest five-year swings in Capital Leases: fell 0.63% in 2022 and later dropped 1.67% in 2025.
  • Year by year, Capital Leases stood at $3.6 million in 2021, then dropped by 0.63% to $3.6 million in 2022, then decreased by 0.94% to $3.6 million in 2023, then decreased by 1.28% to $3.5 million in 2024, then dropped by 1.67% to $3.5 million in 2025.
  • Business Quant data shows Capital Leases for BNGO at $3.5 million in Q4 2025, $3.5 million in Q3 2025, and $3.5 million in Q2 2025.